FDA Approves Eli Lilly’s Obesity Pill, Intensifying Rivalry with Novo Nordisk
The FDA has officially approved Eli Lilly’s obesity pill, intensifying competition with Novo Nordisk’s Wegovy. This approval marks a significant step in the rapidly evolving obesity treatment market.
Eli Lilly’s Approval and Product Details
The newly approved drug, named orforglipron, will be marketed as Foundayo. It received approval under the FDA’s fast-track program, aimed at drugs that align with public health needs.
During Phase 3 trials, orforglipron was tested in capsule form with doses reaching 36 mg. Ultimately, the FDA approved it in tablet form, with dosages up to 17.2 mg, which the company claims is equivalent to the capsule doses.
Market Rivalry: Orforglipron vs. Wegovy
The weight loss market has recently been dominated by injectable medications like Wegovy and Zepbound from Novo Nordisk and Eli Lilly, respectively. However, both companies are now competing with oral formulations.
- Daily oral treatments are considered less effective compared to weekly injectables.
- Many patients prefer pills over needles, as pills are easier to distribute and do not require refrigeration.
Pricing and Efficacy Comparison
Price is expected to play a crucial role in the competition. Eli Lilly has set the price of Foundayo between $149 and $399 monthly in the cash market. Recently, Lilly announced it would lower its pill price to $299 per month for continuous refills, matching the cash price of Novo’s Wegovy.
In terms of efficacy, the Wegovy pill demonstrated a 13.6% weight loss over 64 weeks, while orforglipron showed an 11.2% weight loss in a 72-week study. Furthermore, Wegovy is also linked to reduced cardiovascular risks, as it shares its active ingredient with the long-established injectable version.
Safety Concerns and Regulatory Context
Orforglipron has been generally considered safe, with common side effects including nausea, vomiting, and diarrhea. Unlike many small molecule drugs, it showed no indications of liver damage during trials.
The approval process for orforglipron has raised some eyebrows regarding political influences on the FDA, as it was expedited through the controversial voucher program. Eli Lilly reportedly sought reassurances from the agency about the status of its applications.
With the growing emphasis on obesity treatments, the competition between Eli Lilly and Novo Nordisk is poised to benefit consumers seeking effective and accessible weight loss solutions.
